Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42
- PMID: 11193164
- DOI: 10.1111/j.1749-6632.2000.tb06936.x
Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42
Abstract
In AD certain brain structures contain a pathological density of A beta protein deposited into plaques. The effect of genetic mutations found in early onset AD patients was an overproduction of A beta 42, strongly suggesting that overproduction of A beta 42 is associated with AD. We hypothesized that an immunological response to A beta 42 might alter its turnover and metabolism. Young PDAPP transgenic mice were immunized with A beta 1-42, which essentially prevented amyloid deposition; astrocytosis was dramatically reduced and there was reduction in A beta-induced inflammatory response as well. A beta 1-42 immunization also appeared to arrest the progression of amyloidosis in older PDAPP mice. A beta immunization appears to increase clearance of amyloid plaques, and may therefore be a novel and effective approach for the treatment of AD.
Similar articles
-
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.Nature. 1999 Jul 8;400(6740):173-7. doi: 10.1038/22124. Nature. 1999. PMID: 10408445
-
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.Am J Pathol. 2001 Aug;159(2):439-47. doi: 10.1016/s0002-9440(10)61715-4. Am J Pathol. 2001. PMID: 11485902 Free PMC article.
-
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.Am J Pathol. 2004 Sep;165(3):937-48. doi: 10.1016/s0002-9440(10)63355-x. Am J Pathol. 2004. PMID: 15331417 Free PMC article.
-
Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.Rejuvenation Res. 2006 Spring;9(1):77-84. doi: 10.1089/rej.2006.9.77. Rejuvenation Res. 2006. PMID: 16608400 Review.
-
Neurodegenerative Alzheimer-like pathology in PDAPP 717V-->F transgenic mice.Prog Brain Res. 1998;117:327-34. Prog Brain Res. 1998. PMID: 9932418 Review.
Cited by
-
Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects.J Alzheimers Dis Rep. 2023 Aug 14;7(1):873-899. doi: 10.3233/ADR-230025. eCollection 2023. J Alzheimers Dis Rep. 2023. PMID: 37662616 Free PMC article. Review.
-
Vascular consequences of passive Abeta immunization for Alzheimer's disease. Is avoidance of "malactivation" of microglia enough?J Neuroinflammation. 2005 Jan 11;2(1):2. doi: 10.1186/1742-2094-2-2. J Neuroinflammation. 2005. PMID: 15644140 Free PMC article.
-
Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9295-9. doi: 10.1073/pnas.151242598. Epub 2001 Jul 24. Proc Natl Acad Sci U S A. 2001. PMID: 11470893 Free PMC article.
-
Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.Pharm Res. 2011 Jul;28(7):1696-706. doi: 10.1007/s11095-011-0405-x. Epub 2011 Mar 18. Pharm Res. 2011. PMID: 21424161
-
Spines, plasticity, and cognition in Alzheimer's model mice.Neural Plast. 2012;2012:319836. doi: 10.1155/2012/319836. Epub 2011 Nov 28. Neural Plast. 2012. PMID: 22203915 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical